Curve's Microcycle™ platform enables direct screening of genetically encoded microcycle libraries against disease-associated targets in their native environment inside mammalian cells, which transforms the discovery of first-in-class small molecule therapeutics. By doing so, Curve is building a pipeline of novel cancer drugs to address high priority, therapeutically relevant cancer targets, including intracellular protein-protein and protein-gene interactions. The company's mission is to broaden the landscape of disease targets that can be drugged and to enable the medical industry to get a cure against a number of challenging cancer targets.